# Elicio Therapeutics, Inc.: overview

ELTX · Nasdaq · CIK 1601485 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eltx.md) · [Financials](/companies/eltx/financials.md) · [Filings](/companies/eltx/filings.md) · [Insiders](/companies/eltx/insiders.md)

Latest reported revenue: [$0](/filings/0001601485-23-000035.md) for Q1 FY2023, three months to 2023-03-31, from the 10-Q filed May 10, 2023 (XBRL us-gaap:Revenues, accession 0001601485-23-000035).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(1.39)](/filings/0001601485-25-000124.md) | not reported | [(0.87)](/filings/0001601485-26-000042.md) | [(0.66)](/filings/0001601485-26-000056.md) | [(0.60)](/filings/0001601485-25-000124.md) | not reported | [(0.65)](/filings/0001601485-26-000042.md) | [(0.43)](/filings/0001601485-26-000056.md) |
| Free cash flow | $m | [(7.3) d](/filings/0001601485-25-000124.md) | [(8.8) d](/filings/0001601485-26-000027.md) | not reported | not reported | [(11.1) d](/filings/0001601485-25-000124.md) | [(6.8) d](/filings/0001601485-26-000027.md) | not reported | not reported |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [28.3](/filings/0001601485-23-000011.md) | [2.3](/filings/0001601485-23-000011.md) | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(138.8%)](/filings/0001601485-23-000011.md) | [(1031.4%)](/filings/0001601485-24-000023.md) | not reported | not reported | not reported |
| Net margin | % | [(192.8%)](/filings/0001601485-23-000011.md) | [(1225.9%)](/filings/0001601485-24-000023.md) | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(1.93)](/filings/0001601485-23-000011.md) | [(89.27)](/filings/0001601485-24-000023.md) | [(6.96)](/filings/0001601485-25-000049.md) | [(4.25)](/filings/0001601485-26-000027.md) | [(2.58)](/filings/0001601485-26-000027.md) |
| Free cash flow | $m | [(53.0)](/filings/0001601485-23-000011.md) | [(22.8)](/filings/0001601485-24-000023.md) | [(32.8)](/filings/0001601485-25-000049.md) | [(37.2)](/filings/0001601485-26-000027.md) | [(37.0)](/filings/0001601485-26-000027.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/eltx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Knoll Capital Management, LLC](/funds/1325083.md) | 2026-06-30 | $4.7m | 1,211,957 |  | Added +581,042 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.0m | 766,005 |  | Added +715,408 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.2m | 572,151 |  | Added +53,513 |
| [Caption Management, LLC](/funds/1706766.md) | 2026-06-30 | $1.6m | 418,100 | Call | New +418,100 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.2m | 311,354 |  | Added +176,190 |
| [TORONTO DOMINION BANK](/funds/947263.md) | 2026-06-30 | $782.0k | 200,000 | Call | New +200,000 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $709.3k | 181,400 | Call | Reduced −76,500 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $701.5k | 179,420 |  | Added +128,800 |
| [Caption Management, LLC](/funds/1706766.md) | 2026-06-30 | $647.9k | 165,700 | Put | New +165,700 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $600.6k | 153,600 | Put | Added +140,000 |

## Recent filings

[All 382 filings](/companies/eltx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-09 | 20:05 ET | [DEF 14A](/filings/0001601485-26-000061.md) | Proxy statement, period 2025-12-31 | 0001601485-26-000061 |
| 2026-09-14 | 20:03 ET | [8-K](/filings/0001601485-26-000058.md) | 5.08 Item not in the standard list; 8.01 Other events | 0001601485-26-000058 |
| 2026-08-13 | 20:08 ET | [10-Q](/filings/0001601485-26-000056.md) | Quarterly report, period 2026-06-30 | 0001601485-26-000056 |
| 2026-08-13 | 20:06 ET | [8-K](/filings/0001601485-26-000055.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001601485-26-000055 |
| 2026-07-02 | 10:20 ET | [8-K](/filings/0001104659-26-080058.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-080058 |
| 2026-06-24 | 20:05 ET | [8-K](/filings/0001601485-26-000050.md) | 7.01 Regulation FD disclosure | 0001601485-26-000050 |
| 2026-06-17 | 12:03 ET | [8-K](/filings/0001601485-26-000048.md) | 8.01 Other events | 0001601485-26-000048 |
| 2026-06-15 | 13:21 ET | [8-K](/filings/0001601485-26-000046.md) | 8.01 Other events | 0001601485-26-000046 |
| 2026-05-11 | 20:12 ET | [10-Q](/filings/0001601485-26-000042.md) | Quarterly report, period 2026-03-31 | 0001601485-26-000042 |
| 2026-05-11 | 20:09 ET | [8-K](/filings/0001601485-26-000041.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001601485-26-000041 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001601485-26-000027.md), filed Mar 12, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1601485
- Tickers: ELTX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.